Protocol Ledger

NCT06980025 · Phase III · RECRUITING

Aspirin Dose Escalation for the Prevention of Recurrent Preterm Delivery Trial

Interventional Phase III clinical trial protocol NCT06980025 sponsored by The George Washington University Biostatistics Center in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-07-01 Enrollment: 1,800 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06980025
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,800 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06980025
Protocol FieldVerified Registry Value
NCT IdentifierNCT06980025
Consolidated Lead SponsorThe George Washington University Biostatistics Center
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment1,800 participants (ESTIMATED)
Registered Start Date2025-07-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI